Initiator Pharma A/S
Climate Impact & Sustainability Data (2016-05-02 to 2016-11-30)
Reporting Period: 2016-05-02 to 2016-11-30
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- Complete clinical Phase II study (Proof-of-Concept) (2020).
- Outlicense or sell the drug candidate or the company (after Phase II).
Medium-term Goals:
- Apply for regulatory approval to initiate a clinical Phase I study (2018).
- Initiate and complete clinical Phase I study (2018).
- Initiate clinical Phase II study (Proof-of-Concept) (2019).
Short-term Goals:
- Complete pharmacological work and regulatory toxicology and safety studies for IPED2015 (2017).
Environmental Challenges
- Relatively new company with new contacts, making long-term relationships difficult to assess.
- No launched drugs, making sales potential difficult to assess.
- High financing needs for research and development.
- Risks associated with clinical trials, including delays and uncertain outcomes.
- Product liability risks.
- Risks related to obtaining regulatory approvals.
- Risks associated with suppliers and manufacturers.
- Risks associated with the loss of key personnel.
- Risks associated with competition from multinational pharmaceutical companies.
- Risks associated with patent protection.
- High development costs.
- No prior public trading of the stock, making it difficult to predict trading interest.
- Potential for significant stock price fluctuations.
- No dividend payouts yet.
- Potential conflicts of interest due to board members owning shares.
- Unsecured subscription commitments.
- Potential for stock sales by major shareholders, board members, and management.
- Trading on AktieTorget, an MTF platform with lower regulatory requirements than a regulated market.
Mitigation Strategies
- Securing funding through a new share issue (20.5 MSEK).
- Developing alternative sourcing strategies (implied by risk mitigation discussion).
- Building a largely virtual structure to minimize costs.
- Seeking additional funding through investments and collaborations (e.g., Innobooster program).